ITP About

For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

 

Example prescription depicts a starting dose.

DOPTELET® (avatrombopag) IS THE ONLY ORAL TPO-RA WITHOUT FOOD-TYPE RESTRICTIONS1

As an oral tablet, DOPTELET offers ease of administration for your patients

  • One dosage strength helps make titration manageable for you and your patients
  • DOPTELET is the only oral TPO-RA without food-type restrictions
    • No calcium or other food restrictions
  • DOPTELET does not require additional liver-function monitoring
    • No significant hepatotoxicity seen in clinical trials with DOPTELET
  • No office visit for DOPTELET administration required

Monitor platelet counts weekly until a stable platelet count of ≥50×109/L is achieved, then obtain platelet counts monthly thereafter.

Learn more about dosing, titration, and monitoring >

TPO-RA=thrombopoietin receptor agonist.

ORAL ADMINISTRATION THAT FITS YOUR PATIENTS' LIFESTYLES1,2

DOPTELET must be taken with food.

DOPTELET is not a chelation agent. There are no administration concerns with minerals such as calcium and magnesium.

Your patients can eat the foods they prefer on their own schedules.

UPDATED INTERNATIONAL CONSENSUS AND ASH GUIDELINES3,4

  • The American Society of Hematology (ASH) 2019 guidelines for immune thrombocytopenia and the updated International Primary ITP Consensus Report have been published3,4
    • The ASH guidelines recommend the use of TPO-RAs as a second-line therapy4
    • The updated International Primary ITP Consensus Report recommends the use of TPO-RAs as a therapy subsequent to initial therapy3
 

View the ASH 2019 ITP guidelines and updated International Consensus Report at AshPublications.org/BloodAdvances

DESIGNED TO WORK WITH THE BODY TO INCREASE PLATELET COUNTS THROUGH ORAL DOSING1

DOPTELET helps patients produce more of their own platelets

Doptelet Efficacy

DOPTELET® (avatrombopag) Efficacy

Discover how DOPTELET increased platelet counts in the clinical trial.1

References:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.

2. Data on file. Dova Pharmaceuticals, Inc.

3. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2019;3(22):3780-3817.

4. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood. 2019;3(23):3829-3866.

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

In clinical trials, 7% (9/128) of patients with chronic immune thrombocytopenia treated with DOPTELET developed a thromboembolic event. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic immune thrombocytopenia in an attempt to normalize platelet counts. Follow the dosing guidelines to achieve target platelet counts.

Contraindications:  None

Drug Interactions  

Dose adjustments are recommended for patients with chronic immune thrombocytopenia taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.

Adverse Reactions

The most common adverse reactions (≥10%) were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.

Please see Full Prescribing Information for DOPTELET® (avatrombopag).

Visit Dova.com for WAC pricing.

 
 

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.